Sham Litigation Claims Nixed In Androgel Pay-For-Delay MDL
Law360, New York (September 28, 2012, 5:51 PM EDT) -- A Georgia federal judge on Friday dismissed antitrust allegations that Solvay Pharmaceuticals Inc. filed sham patent infringement litigation against generic rivals in order to delay the entry of competing versions of Androgel from the market through a reverse payment settlement.
U.S. District Judge Thomas W. Thrash granted the defendants — Solvay and generics makers Par Pharmaceutical Cos. Inc., Paddock Laboratories Inc. and Watson Pharmaceuticals Inc. — summary judgment on the private plaintiffs' remaining claims in the antitrust case, originally instigated by a Federal Trade Commission investigation.
The judge had already dismissed claims by the FTC and purchasers of the testosterone replacement...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!